oral, ultralong-acting insulin analog
effective in Ph. IIa, hum. t1/2~3 d, 4% F dog
albumin-binding motif + reduced endocytosis
J. Med. Chem., Dec. 28, 2020
Novo Nordisk, Maaloev, DK
Home > OI338
oral, ultralong-acting insulin analog
effective in Ph. IIa, hum. t1/2~3 d, 4% F dog
albumin-binding motif + reduced endocytosis
J. Med. Chem., Dec. 28, 2020
Novo Nordisk, Maaloev, DK
Novo oral insulin analog
You don’t have time to read everything, but you can’t afford to fall behind.
Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.
Get ahead now by requesting a trial.
Molecules of the Month